Response rate higher but more adverse events seen at week 12 in patients with plaque psoriasis receiving tapinarof versus vehicle control
Treatments Explored for Moderate-to-Severe Alopecia Areata
Improvement in lesional scalp transcriptome toward nonlesional profile seen at week 24 for both ritlecitinib, brepocitinib
Psoriasis Ups Risk for Vascular Disease, Venous Thromboembolism
Risk particularly high in women and individuals with psoriatic arthritis
Female Physicians Estimated to Earn $2 Million Less Over 40-Year Career
Difference in annual income observed in simulations most rapid during the initial years of practice
Genetic Diagnosis of Rare Diseases Up With Genome Sequencing
Diagnostic yields were higher for disorders likely to have a monogenic cause versus those with a complex cause
Women Underrepresented in U.S. Health System Leadership
Findings seen among the largest U.S. health systems, insurance groups, and U.S. Department of Health and Human Services
Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma
Two-year overall survival 72 percent for those starting with N/I, 52 percent for those starting with dabrafenib/trametinib
- Page 2 of 2
- 1
- 2